2022
   Ljubljana, Slovenia

II-01 Bram Agema Improving the tolerability of osimertinib by identifying its toxic limit Wednesday 15:10-16:40

II-02 Doaa Ahmed Mohamed Development of a physiologically based pharmacokinetic model for intratumoral biodistribution of magnetic iron oxide nanoparticles Wednesday 15:10-16:40

II-06 Claire Brillac Selection of isatuximab dosing regimen in pediatric patients with leukemia using population PK and PBPK modeling approaches Wednesday 15:10-16:40

II-07 René Bruno Comparison of two-stage and joint TGI-OS modelling using data from six clinical studies in metastatic non-small cell lung cancer patients Wednesday 15:10-16:40

II-08 Aurore CARROT A joint K-PD model with the tumor size changes and CA-125 kinetics in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study. Wednesday 15:10-16:40

II-09 Marc Cerou Semi-mechanistic pharmacokinetic-pharmacodynamic modeling of tumor size dynamics in advanced breast cancer patients treated with single-agent amcenestrant Wednesday 15:10-16:40

II-11 S. Y. Amy Cheung Exposure-Response Analysis of Tovorafenib (DAY101) Relating Objective Response to Exposure, Patient- and Disease Characteristics Wednesday 15:10-16:40

II-13 Christian Hove Claussen Modeling Mouse Xenograft Tumor Growth Inhibition to Optimize Cycles in Oncology Wednesday 15:10-16:40

II-14 David Damoiseaux Physiologically based pharmacokinetic model to predict chemotherapy exposure in infants through breastfeeding: paclitaxel as an example Wednesday 15:10-16:40

II-15 Liu Dan Population pharmacokinetics of selpercatinib in patients with an advanced solid tumor, including RET fusion-positive NSCLC, RET-mutant MTC, and other tumors with increased RET activity Wednesday 15:10-16:40

II-16 Lekshmi Dharmarajan Preclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C Wednesday 15:10-16:40

II-18 Yin Edwards Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors Wednesday 15:10-16:40

II-23 Ana-Marija Grisic Model-informed noninferiority of cetuximab biweekly to weekly dosing regimen in metastatic colorectal cancer Wednesday 15:10-16:40

II-27 Heeyoon Jung rhIL-7-hyFc dose optimization for chemotherapy-induced lymphopenia using FcRn mediated IgG disposition model Wednesday 15:10-16:40

II-31 Marie Lambert A population approach to compare the impact of two amino acid solutions on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors Wednesday 15:10-16:40

II-32 Félicien Le Louedec Non-linear mixed-effects modeling to evaluate the pre-analytical stability of uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing. Wednesday 15:10-16:40

II-33 Xia Li Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Wednesday 15:10-16:40

II-34 Yu-wei Lin Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers Wednesday 15:10-16:40

II-35 Han Liu Learning dose-response relationship via PK-TS-multistate clinical endpoints modeling framework: application to bintrafusp alfa in second-line non-small cell lung cancer patients Wednesday 15:10-16:40

II-36 Rubin Lubomirov Population pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer Wednesday 15:10-16:40

II-37 Corinna Maier Semi-Mechanistic Model to Aid Clinical Understanding of Myelodysplastic Syndromes Wednesday 15:10-16:40

II-38 Yomna Nassar Cachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study Wednesday 15:10-16:40

II-39 Janine Nijhuis The comparison of pharmacoeconomic and pharmacometric modelling to improve cost-effectiveness assessment of sunitinib in GIST. Wednesday 15:10-16:40

II-40 Qing Xi Ooi Rituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity Wednesday 15:10-16:40

II-41 Antoine Pitoy Joint modeling of longitudinal and time-to-event data for earlier estimation of the primary endpoint in oncology clinical trials: A retrospective analysis of the ICARIA-MM clinical trial Wednesday 15:10-16:40

II-42 Clémence Pouzin Modelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development. Wednesday 15:10-16:40

II-44 Bhaskar Rege Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa (Nemvaleukin), an Investigational Cancer Immunotherapy Wednesday 15:10-16:40

II-45 Elisabeth Rouits Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma Wednesday 15:10-16:40

II-46 Javier Sanchez Fernandez Preclinical in vivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-Cell bispecific in combination with anti-PD-L1 Wednesday 15:10-16:40

II-47 Aymara Sancho Characterizing the interplay between biological factors and cell growth in unperturbed tumor growth dynamics Wednesday 15:10-16:40

II-48 Celine Sarr A framework for prediction of progression free survival based on modelling of sub-endpoints Wednesday 15:10-16:40

II-51 Stephan Schaller A PB-QSP platform model for T cell-dependent bispecific antibodies Wednesday 15:10-16:40

II-53 Hinke Huisman-Siebinga A Population Pharmacokinetic Model Using Imaging Data to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients Wednesday 15:10-16:40

II-54 Zhiyuan Tan Population Pharmacokinetics of cabozantinib in adult metastatic renal cell carcinoma patients: evaluation of real-world data Wednesday 15:10-16:40

II-55 David Ternant Influence of immunization on the pharmacokinetics of monoclonal antibodies : anti-drug antibody-mediated drug disposition (ADAMDD) of rituximab in mice Wednesday 15:10-16:40

II-57 Elena Tosca A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera. Wednesday 15:10-16:40

II-59 Maarten Van Eijk Optimizing the value of preclinical data for the design of first-in-human clinical studies with oral cabazitaxel through population pharmacokinetic modelling Wednesday 15:10-16:40

II-63 Anyue Yin Quantitative modelling of exposure-tumor dynamics relationship and development of drug resistance in non-small cell lung cancer patients treated with erlotinib Wednesday 15:10-16:40